RT @LukeJelen: 1/ Just out in @NatureMedicine : we show the opioid system modulates ketamine’s effects in major depressive disorder, with n….

Pramipexole vs. quetiapine vs. amantadine in TRD. Interesting open label, short term RCT using a surprisingly low dose (I suspect that the reported dose of 37.5mg of pramipexole is a typo and it should be 0.375mg).

Join millions who have switched to Grok.

RT @pash22: Can administrative real-world data substitute for RCTs and offer propensity matching to reduce bias? .Results often fail to cor….

RT @LifeSciVC: Big late stage win for Takeda! . Oveporexton (TAK-861) hits on all endpoints in narcolepsy for the first-in-class orexin re….

RT @awaisaftab: “Basically, if you are still someone who treats the Davies and Read estimate of antidepressant withdrawal as valid—take the….

RT @awaisaftab: Playing Whack-a-Mole With the Uncertainties of Antidepressant Withdrawal. Complacency is the wrong conclusion of a new deba….

RT @JAMAPsych: Systematic review and meta-analysis: Stopping antidepressants leads to slight symptom increases compared to placebo, but the….

RT @OxHealthBRC: 🎊Recently, colleagues from across the @NIHRresearch Mental Health Translational Research Collaboration (MH-TRC) gathered f….

RT @Rational_Psych: In February, I saw @michaelbrowni19 present the results of PAX-D, a randomised controlled trial of pramipexole in treat….

Paper is here:

🔬GRATEFUL to @NIHRresearch for funding this work and @OxHealthBRC for support. Pramipexole is clearly not a first line treatment for depression, but these results demonstrate that it can be a useful option for our most treatment-resistant patients! 6/6.

⚠️TRANSPARENCY: There are challenges to using pramipexole: 20% stopped pramipexole due to side effects vs 5% placebo. Most common: nausea, headache, dizziness, sleep problems. 5/6.

🧠OUR HYPOTHESIS: We targeted dopamine D2/3 receptors with pramipexole instead of the usual serotonergic approach. Dopamine is crucial for reward/pleasure - and anhedonia (can't feel pleasure) is often what persists even after other depression symptoms improve. 4/6.

🎯WHY WE DID THIS: About 30% of our patients don't respond to first-line antidepressants. We recruited people with chronic depression (median 8.5 years) who had tried 3-4 medications without success. These are the patients we struggle to help most. 3/6.

💊OUR FINDINGS: In our randomized controlled trial (n=150), patients receiving pramipexole showed:.6.4-point reduction in QIDS scores vs 2.4 for placebo (p<0.0001).44% response rate vs 16% placebo.28% remission vs 8% placebo .Effect size d=0.87 - this is substantial! 2/6.

🧵THREAD: Our new study published in #lancetpsych! We found that pramipexole augmentation substantially reduced depressive symptoms in patients with treatment-resistant depression over 48 weeks of treatment. This is an important advance in how we treat depression! 1/6.

RT @MaximeTaquet: 📷.🧠💉 Shingrix (shingles vaccine) may reduce dementia risk—possibly thanks to its adjuvant, AS01. In a new study, we found….

RT @ariehkovler: Trump's Justice Department is writing to academic journals (this one is a journal about chest diseases) demanding they pub….

RT @RyanYAN_98: Big shout out to the wonderful team, Ni Xu (co-first), Kate Saunders, John Geddes, and @michaelbrowni19! Read our open-acc….

RT @docqhuys: Excited to announce a postdoc position to use EEG+RL to identify specific mechanisms of different antidepressants within a la….